ARMYDA-RECAPTURE：PCI前の高用量スタチン

ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) トライアルは、PCI施行中の安定狭心症患者で、PCI周術心筋梗塞発生を短期的に減少させ、この心筋防御作用は、ARMYDA-ACS（Atorvastatin for Reduction of Myocardial Damage During Angioplasty–Acute Coronary Syndromes）で示されてた。

今回はやや長期の報告

Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention
Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial
J Am Coll Cardiol, 2009; 54:558-565, doi:10.1016/j.jacc.2009.05.028 (Published online 1 July 2009).

介入：192名：atorvastatin reload (80 mg 12 h before intervention, with a further 40-mg pre-procedural dose [n = 192])
プラセボ：191名

30日の重大大血管イベント発生比をオッズ比　０．５０（９５％　信頼区間　０．２０－０．８０，p=0.039
で、内訳の８０％が急性冠症候群


Secondary End Points(cardiac death, myocardial infarction, or unplanned revascularization)